Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015; Provides Revenue Guidance for the Year Ending December 31, 2016
For the year, the company reported total Revenues were USD 21.39 million against USD 32.39 million a year ago. Loss before income taxes was USD 37.61 million against income of USD 19.67 million a year ago. Net loss was USD 37.78 million against income of USD 19.67 million a year ago. Diluted loss per common share was USD 1.16 against income of USD 0.60 a year ago.
For the year ending December 31, 2016, assuming foreign currency exchange rates remain at or near current levels, the company currently expects net revenues to be in the range of USD 48 million to USD 58 million.